|
|
|
We recap Day 1 of the 2025 BIO CEO and Investor Conference in New York with exciting developments on obesity drugs and AI. (203 words, 1 minute, 0 seconds)
|
|
|
|
How to follow the BIO CEO & Investor Conference |
|
|
|
|
|
What’s next for obesity drugs |
|
|
|
Obesity drugs are a major growth area for the biopharma industry, according to a BIO CEO 2025 panel of innovators in the field. The panel: “Obesity: Next Medicines with Impact.”
The takeaway: Five innovative programs were showcased, two involving GLP-1-based drugs and three others approaching weight loss from different angles. Panelists spoke of the unmet needs their products addressed and the huge potential in the space.
What they’re saying: “This is going to be a $100-$150 billion class of medications, perhaps the largest class of therapeutics we have ever seen in the biotechnology industry,” said moderator Michael Yee. Read more on Bio.News. |
|
|
What AI can and can’t do in drug discovery |
|
|
|
When used well, AI can hypercharge drug discovery, but it’s important to understand the limits of this tool along with its strengths, innovators told BIO CEO 2025 yesterday. The panel: “AI’s Utility in Pharmacokinetics and Biomarker Selection.”
The takeaway: AI can’t develop drugs on its own but it’s a powerful tool. Humans need to control the process and provide the best data. AI’s contribution can include providing logical solutions that avoid potential human bias in some cases.
What they’re saying: “When you make human pictures with AI, what happens?” asked Maria Luisa Pineda, Envisagenics CEO. “Most of the images of humans end up with six fingers, right? So imagine antibodies, or CAR-Ts, or RNA having that metaphorical extra sixth finger.” Read more on Bio.News. |
|
|
|
|
|
|
|
|
|
